Next-level therapies to elevate care

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients.

Sonelokimab (a.k.a. M1095, ALX-0761) unleashes the full power of IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Sonelokimab moves the clinical paradigm beyond the traditional antibodies, designed to directly target sites of inflammation and penetrate difficult-to-reach inflamed tissues and joints.

MoonLake builds on a robust clinical data built in recent years by Ablynx, a Sanofi company, and Merck KGaA. MoonLake licensed Sonelokimab from the latter, with full global rights and including a favorable IP position.

The team at MoonLake has a long history and experience with developing immunology assets and growing businesses around new technologies. As a clinical-stage company we are continuously growing and looking for excellent and experienced talent.

The terms Nanobody® and Nanobodies® are trademarks of Ablynx, a Sanofi company.


Creating novel therapies to better lives

We do stellar science

We aspire to create novel therapies that elevate treatment horizons, with innovative science, and high quality, always.

We value people that are:

  • Uniquely experienced and committed to do things cleverly
  • Accountable and responsible for their area of expertise and the team as a whole
  • Able to balance results delivery with scientific precision, ethical rigour & transparency

We go beyond

We aspire to be positively disruptive in our field, and bold in the way we challenge the norms and each other.

We value people that are:

  • Excited about stepping up to new challenges, at speed
  • Courageous in thinking of how the team can achieve the impossible
  • Curious to ask questions and challenge each other to find new solutions

We unlock value

We aspire to create long-term value for our investors and our communities.

We value people that are:

  • Dedicated to relentlessly create value for MoonLake and our investors
  • Driven to results with executional mastery and integrity, for the benefit of our community
  • Focused on continuously growing as individuals and as a team

Executive Officers

Jorge Santos da Silva
Chief Executive Officer
Kristian Reich
Chief Scientific Officer
Matthias Bodenstedt
Chief Financial Officer
Nuala Brennan
Chief Clinical Development Officer
Oliver Daltrop
Chief Technology Officer


Jorge Santos da Silva
Chief Executive Officer
Simon Sturge
Chairman & Chairperson of The Nominating & Corporate Governance Committee
Catherine Moukheibir
Chairperson of The Audit Committee
Andrew J. Phillips
Chairperson of The Compensation Committee
Spike Loy
Kara Lassen
Ramnik Xavier